Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer. - Wikidata - wikimedia - TriplyDB

Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer.

Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer.

http://www.wikidata.org/entity/Q33347194

about

Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metastases.A dose escalation study of docetaxel plus capecitabine in combination with oxaliplatin in patients with advanced solid tumors.Docetaxel plus oxaliplatin in combination with capecitabine as first-line treatment for advanced gastric cancer.A Muti-center, Randomized Phase II Study of Oxaliplatin and S-1 versus Capecitabine and Oxaliplatin in Patients with Metastatic Colorectal Cancer.Phase II study of oxaliplatin combined with S-1 and leucovorin (SOL) for Chinese patients with metastatic colorectal cancer.A phase I study of an oral simulated FOLFOX with high dose capecitabine.A phase II study of oxaliplatin, dose-intense capecitabine, and high-dose bevacizumab in the treatment of metastatic colorectal cancer First-in-human phase II trial of the botanical formulation PHY906 with capecitabine as second-line therapy in patients with advanced pancreatic cancer.Mesenchymal stem cells genetically modified by lentivirus-mediated interleukin-12 inhibit malignant ascites in mice.Dose-intense capecitabine, oxaliplatin and bevacizumab as first line treatment for metastatic, unresectable colorectal cancer: a multi-centre phase II study Bevacizumab in combination with biweekly capecitabine and irinotecan, as first-line treatment for patients with metastatic colorectal cancer.A phase II study of oxaliplatin, 5-fluorouracil, leucovorin, and high-dose capecitabine in patients with metastatic colorectal cancer.Oral Xeloda plus bi-platinu two-way combined chemotherapy in treatment of advanced gastrointestinal malignancies Emerging drugs in pancreatic cancer.Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study.A review of oxaliplatin and its clinical use in colorectal cancer.Capecitabine: the new generation of fluoropyrimidines in colorectal cancer.A randomized, phase II trial of standard triweekly compared with dose-dense biweekly capecitabine plus oxaliplatin plus bevacizumab as first-line treatment for metastatic colorectal cancer: XELOX-A-DVS (dense versus standard)Survival of untreated advanced colorectal cancer patients.Capecitabine: effective oral fluoropyrimidine chemotherapy.Drug Insight: Metastatic colorectal cancer--oral fluoropyrimidines and new perspectives in the adjuvant setting.Comparison of efficacy of different route of administration of chemotherapy on unresectable, advanced gastric cancer Optimal treatment of metastatic colorectal cancer.The neurokinin1 receptor antagonist aprepitant as an antiemetic for moderately emetogenic chemotherapy.A phase II study of biweekly dose-intensified oral capecitabine plus irinotecan (bXELIRI) for patients with advanced or metastatic gastric cancer.A phase II study of capecitabine plus 3-weekly oxaliplatin as first-line therapy for patients with advanced gastric cancer.A phase I and II study of 2-weekly irinotecan with capecitabine in advanced gastroesophageal adenocarcinoma.Side effects during chemotherapy predict tumour response in advanced colorectal cancer Capecitabine and oxaliplatin in combination as first- or second-line therapy for metastatic breast cancer: a Wisconsin Oncology Network trial.A review of the role of capecitabine in the treatment of colorectal cancer.Phase I clinical and pharmacokinetic study of oxaliplatin, irinotecan and capecitabine.Assessment of Tumor Response and Resection Rates in Unresectable Colorectal Liver Metastases Following Neoadjuvant Chemotherapy with Cetuximab Capecitabine plus oxaliplatin for the treatment of colorectal cancer.Antiangiogenic agents in first-line and second-line therapy for advanced colorectal cancer.A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer XELOX in colorectal cancer: a convenient option for the future?Retrospective analysis of the effect of CAPOX and mFOLFOX6 dose intensity on survival in colorectal patients in the adjuvant setting.Docetaxel, capecitabine and carboplatin in metastatic esophagogastric cancer: a phase II study.Multicenter randomized phase II clinical trial of oxaliplatin reintroduction as a third- or later-line therapy for metastatic colorectal cancer-biweekly versus standard triweekly XELOX (The ORION Study).

P2860

Q24815800-B679F3D0-4354-44D6-8E37-87B0C628F7BD Q33330997-35C6BA52-6D2E-49A5-9F69-0B992F542CE0 Q33386694-354E49FE-2FCF-4D32-B765-ED3F9C745B72 Q33396506-CAA480A5-C4C2-485E-983E-52204F9283C1 Q33425826-A655AC78-248E-4EE8-A4C3-734171753987 Q33428967-1C0C6DB8-DF1A-4B73-80A3-CBF1C0DE00DA Q33973344-DC090810-1C93-430A-A960-909B3F18CA1B Q33998072-24AAE12F-26E3-451E-836E-34735FA6D855 Q34008520-41747142-26D9-49B8-A29F-E56270DCD944 Q34119602-0AF319F7-4138-4ED1-8151-36C640DBCDA4 Q34317249-8573799B-628C-4D97-8C88-6B521C378B01 Q34343967-09E05A68-515E-445B-8136-795DA07535D1 Q34682635-33929997-7DFC-4287-B7DC-4527B4E836BC Q35615863-4611CDE0-0156-44FC-B844-9788ACB76238 Q35779283-2E39D06B-B10A-4805-9611-D44F436426A1 Q35807573-C7399114-B3F1-4A55-9F62-77A6C2F492F5 Q35906940-6CFADF93-B6A0-4A61-AAB7-E133E4B4E154 Q35987726-A8543FC3-EDFB-4F5B-8303-014C8F14F2BC Q36102819-9A56B24E-3514-4B79-9063-329DC05834E2 Q36120932-CDB6FA48-2E8B-400A-9CF4-4E0F25FA54DD Q36164013-11BABEE9-F9B8-4376-AB7C-F93BDBFE30B7 Q36306269-E1B7FDF6-8ACC-4BBF-9C1E-A74C9DEC3D23 Q36402491-44FB6811-DB11-415F-B6DF-E21BD6DED966 Q36499255-62D428C4-50D7-452A-97EF-9A80CC128897 Q36548740-0D9E78E0-439D-4C8F-B088-BA7A7E9CD4A4 Q36609591-A8EB0CC0-6EA2-42E6-B462-9C99D721E48E Q36614036-AF47E10E-B4F0-4957-9A84-CD40ABB105BF Q36614602-AFB47E0D-B268-4303-9D47-C58FAC60EB3A Q36615421-213DD6F4-9FAA-46CC-8963-26FC408A3EC3 Q36636872-F0939929-87C5-499E-AB24-BB9C43CE260A Q36661290-D28156C3-3AFE-44F0-9887-6F209A7DCFE9 Q36677787-A129419D-D312-47D3-84A4-261279C90EE4 Q36739940-E35E789E-6A71-499F-9171-E3B3DAB8EC15 Q37085987-5C37AB7C-446D-41C8-88BB-106714B1DAE5 Q37153292-0ADE852C-D638-4768-B59C-76BA3201361B Q37225701-57D40689-FE97-4D1D-90DC-B4EC1212B4AB Q37839084-62D9D83B-1498-458D-AB26-EE1D3591DEF3 Q38872765-430F94E4-9A42-4619-9B69-6E573F9B3F89 Q40172287-30D98520-ECE5-4698-9755-698FE0926F13 Q41207847-30A03E08-CB79-4400-9CA4-B0ADCEC09BAD

P2860

Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer.

http://www.wikidata.org/entity/Q33347194

description

2003 nî lūn-bûn

@nan

2003 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Randomized multicenter phase I ...... in advanced colorectal cancer.

@ast

Randomized multicenter phase I ...... in advanced colorectal cancer.

@en

type

label

Randomized multicenter phase I ...... in advanced colorectal cancer.

@ast

Randomized multicenter phase I ...... in advanced colorectal cancer.

@en

prefLabel

Randomized multicenter phase I ...... in advanced colorectal cancer.

@ast

Randomized multicenter phase I ...... in advanced colorectal cancer.

@en

P1433

Q33347194-5365218A-0C10-4E7B-8FBE-B97DE29932E8

P1476

Q33347194-BCE1AD4B-DD2B-4ABA-81E0-2A91FAC32F92

P2093

Q33347194-07CFB2F8-9F24-4F6A-951B-BB0A871889DB

Q33347194-371FDFC9-5D6A-437D-B85B-B82335BB8DCA

Q33347194-40D0480A-A83F-4A3C-B2E4-51EAC49B6753

Q33347194-73F57B45-4285-48A9-93EB-6C343CD895F2

Q33347194-9BE5C9A9-0386-40C4-BB12-D2AB4F6191FA

Q33347194-AA357256-64A8-4733-B097-77485D7EAD64

Q33347194-CB5AC323-6AE5-4C95-B240-420CB3C5EC75

Q33347194-D8F8D9A4-0903-4600-90E8-DCDC7D2F6C72

Q33347194-DAFDC32F-03D4-4980-90E3-E581EE4D8860

Q33347194-E04BB25F-418A-4671-8C37-1ED25DA3E8E4

P304

Q33347194-D2E45A80-550D-4F9D-9C57-0419ACB4E5A5

P31

Q33347194-CD210A0A-D6D4-434A-A1A7-EC8749E54394

P356

Q33347194-71DCC55B-6038-40D3-BFF7-4C902DDC5283

P407

Q33347194-23CB2296-3468-4BD7-95DB-20E864FF91F6

P433

Q33347194-8798E1E4-E978-444E-9C16-0CDFF84297FD

P478

Q33347194-0798C923-CAC5-44B2-A4D8-5837D8534409

P577

Q33347194-6CB33823-3F09-4825-8F8F-F7D1E4608723

P698

Q33347194-C3E59F79-A393-44CB-984F-A498E38498BD

P921

Q33347194-06FF8458-EC9E-49E0-A05B-061C9D5CF9C2

Q33347194-8EC1EDDC-E10A-40B4-AC14-9CC1313EB59A

Q33347194-D0607966-50F3-416E-AE76-D0F6110E300B

P356

JCO.2003.09.016

P1433

Journal of Clinical Oncology

P1476

Randomized multicenter phase I ...... in advanced colorectal cancer.

@en

P2093

Alfred Lenauer

http://www.w3.org/2001/XMLSchema#string

Birgit Schüll

http://www.w3.org/2001/XMLSchema#string

Bruno Schneeweiss

http://www.w3.org/2001/XMLSchema#string

Dieter Depisch

http://www.w3.org/2001/XMLSchema#string

Erwin Kovats

http://www.w3.org/2001/XMLSchema#string

Fritz Lang

http://www.w3.org/2001/XMLSchema#string

Gabriela V Kornek

http://www.w3.org/2001/XMLSchema#string

Katharina Schmid

http://www.w3.org/2001/XMLSchema#string

Markus Raderer

http://www.w3.org/2001/XMLSchema#string

Werner Scheithauer

http://www.w3.org/2001/XMLSchema#string

P304

1307-1312

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2003.09.016

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P577

2003-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12663719

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

phase II clinical trial

multicenter trial